TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04303676

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Practice Facilitation with e-Learning
Description: Virtual practice facilitation intervention using e-learning modules to guide the sessions includes:~a. Practice Facilitator (PF) conducts 7 monthly virtual visits with each practice QI team i. Optional: PFs and practices may choose to conduct virtual facilitation in groups of up to 5 practices simultaneously b. MAT training (combination of virtual academic detailing plus online training resource) plus ongoing support to deal with questions through email and/or office hours with our project staff, experts, with additional consultation if needed with an addiction medicine specialist.~c. Resources largely included as part of the e-learning module, but supplemented by online resource hub d. Centralized remote health information technology assistance, focused on implementation of registry functionality to track patients for population management and to report the measures required by AHRQ.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Practice Facilitation without e-Learning
Description: Virtual practice facilitation intervention without e-learning to guide the sessions includes:~a. Practice Facilitator (PF) conducts 7 monthly virtual visits with each practice QI team i. Optional: PFs and practices may choose to conduct virtual facilitation in groups of up to 5 practices simultaneously b. MAT training (virtual academic detailing) plus ongoing support to deal with questions through email and/or office hours with our project staff, experts, with additional consultation if needed with an addiction medicine specialist c. Online resource hub d. Centralized remote health information technology assistance, focused on implementation of registry functionality to track patients for population management and to report the measures required by AHRQ.
Study: NCT03176537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: Androgel (50mg testosterone), gel, daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo, gel, daily
Study: NCT01335737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic training
Description: 12 weeks of aerobic training, 4 times/week

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait list
Description: wait list control condition
Study: NCT04342507

Intervention type: OTHER
Group type: OTHER
Intervention: conservative treatment
Description: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conservative treatment
Description: lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of adults chalazia by re-establishing intestinal and immune homeostasis
Study: NCT03241030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucralfate
Description: Will receive 20mg/kg/dose up to 1 gram.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Will received placebo solution of similar quantity to that of the weight based dose of sucralfate.
Study: NCT00565448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: Pharmaceutical form:solution for infusion~Route of administration:intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Pharmaceutical form:solution for infusion~Route of administration:intravenous
Study: NCT03241030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
Study: NCT04313413

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga sessions includes sukshma vyayama (strengthening yoga expertise), stretching and relaxing postures (asana) on chair or standing, breathing and meditation practices.
Study: NCT01068964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution
Description: One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Bottle 2: Vehicle Ophthalmic Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution
Description: One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost Ophthalmic Solution Bottle 2: 0.5% Timolol Ophthalmic Solution
Study: NCT02091557

Intervention type: DRUG
Intervention: GnRH-analogue
Study: NCT04215302

Intervention type: DEVICE
Intervention: laryngeal mask
Description: the size of laryngeal mask given to the patient was based on patient's weight measurement
Study: NCT00615901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim
Description: C (cyclophosphamide) 600 mg/m2 M (methotrexate) 40 mg/m2 F (fluorouracil) 600 mg/m2 P (PEG-filgrastim ) 6 mg. Eight doses of CMF q 14 days with PEG-filgrastim administered approximately 24 hours after chemotherapy. Day 14, is also considered day 1 of the next cycle.
Study: NCT02902341

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition Therapy
Description: Nutrition based on measured caloric needs.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard protocol nutrition based on calculated caloric needs.
Study: NCT02150434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated oxygen titration
Description: Automated oxygen titration every second to maintain stable SpO2 at a predefined value (94% in the present study)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Compressed air
Description: compressed air delivered at a fixed flow of 2 L/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen constant flow
Description: oxygen delivered at a fixed flow of 2L/min
Study: NCT01627730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pretest and posttest scores
Description: pretest and post-test scores are calculated for relative growth scores
Study: NCT00272987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: (GW572016) 1000 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 80 mg/m2 IV weekly for three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 80 mg/m2 IV weekly for three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 80 mg/m2 IV weekly for three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 4 mg/kg loading dose and 2 mg/kg weekly IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 4 mg/kg loading dose and 2 mg/kg weekly IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 4 mg/kg loading dose and 2 mg/kg weekly IV
Study: NCT00331409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 2.5 mg by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: 600 mg by mouth daily
Study: NCT00662792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium (Tio18GEL)
Description: 18 µg Tiotropium (Tio18GEL) inhalation powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium (Tio18GEL)
Description: 18 µg Tiotropium (Tio18GEL) inhalation powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium (Tio18GEL)
Description: 18 µg Tiotropium (Tio18GEL) inhalation powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium (Tio18GEL)
Description: 18 µg Tiotropium (Tio18GEL) inhalation powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol MDPI (Salm50DPI)
Description: 50 µg Salmeterol MDPI (Salm50DPI) twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol MDPI (Salm50DPI)
Description: 50 µg Salmeterol MDPI (Salm50DPI) twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol MDPI (Salm50DPI)
Description: 50 µg Salmeterol MDPI (Salm50DPI) twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol MDPI (Salm50DPI)
Description: 50 µg Salmeterol MDPI (Salm50DPI) twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium (T18GEL) + Salmeterol MDPI (S_DPI)
Description: 18 µg Tiotropium (T18GEL) inhalation powder plus 50 µg Salmeterol MDPI (S_DPI) twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium (T18GEL) + Salmeterol MDPI (S_DPI)
Description: 18 µg Tiotropium (T18GEL) inhalation powder plus 50 µg Salmeterol MDPI (S_DPI) twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium (T18GEL) + Salmeterol MDPI (S_DPI)
Description: 18 µg Tiotropium (T18GEL) inhalation powder plus 50 µg Salmeterol MDPI (S_DPI) twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium (T18GEL) + Salmeterol MDPI (S_DPI)
Description: 18 µg Tiotropium (T18GEL) inhalation powder plus 50 µg Salmeterol MDPI (S_DPI) twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium/Salmeterol (T+S_PE)
Description: Fixed-dose combination of 7.5 µg/ 25 µg Tiotropium/Salmeterol (T+S_PE) inhalation powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium/Salmeterol (T+S_PE)
Description: Fixed-dose combination of 7.5 µg/ 25 µg Tiotropium/Salmeterol (T+S_PE) inhalation powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium/Salmeterol (T+S_PE)
Description: Fixed-dose combination of 7.5 µg/ 25 µg Tiotropium/Salmeterol (T+S_PE) inhalation powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium/Salmeterol (T+S_PE)
Description: Fixed-dose combination of 7.5 µg/ 25 µg Tiotropium/Salmeterol (T+S_PE) inhalation powder
Study: NCT04196660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Labor Dance
Description: The pregnant women and their spouses were trained about the labor dance in the prenatal training without disclosing any information regarding the delivery and labor pain. The pregnant women and their spouses/partners who wanted to perform the practice were asked to inform the researcher when the labor started. The researcher stayed with the pregnant women and their spouses during the practice and labor process. The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music (on a YouTube channel named Ohgertam Jugrefem) in a dim, silent environment. The spouse or partner massaged the pregnant woman's sacral area while dancing. During the active phase of labor, the pregnant women in the DPMG danced with the midwives who were attendant in the delivery room and who were monitoring the pregnant women's status.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Labor Dance
Description: The pregnant women and their spouses were trained about the labor dance in the prenatal training without disclosing any information regarding the delivery and labor pain. The pregnant women and their spouses/partners who wanted to perform the practice were asked to inform the researcher when the labor started. The researcher stayed with the pregnant women and their spouses during the practice and labor process. The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music (on a YouTube channel named Ohgertam Jugrefem) in a dim, silent environment. The spouse or partner massaged the pregnant woman's sacral area while dancing. During the active phase of labor, the pregnant women in the DPMG danced with the midwives who were attendant in the delivery room and who were monitoring the pregnant women's status.
Study: NCT02681016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DES Calypso
Description: A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Stenosis of coronary artery is passed by the hydrophilic coronary wire. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DES Xience Prime
Description: A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Stenosis of coronary artery is passed by the hydrophilic coronary wire. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angioplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angioplasty
Study: NCT03649399

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Abdominal ultrasound
Description: Abdominal ultrasound for detection of the pancreatic stent
Study: NCT04821804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HYADENT BG)
Description: the operator topically applied the HYADENT BG on the borders of the graft after stabilization.~on the donor site and injection of HYADENT BG in collagen sponge that was placed over the site, then figure X sutures to close the area using (4-0 polyglycolic acid/ reverse cutting/ 12 mm) resorbable sutures

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyaluronic Acid (HYADENT BG)
Description: the operator topically applied the HYADENT BG on the borders of the graft after stabilization.~on the donor site and injection of HYADENT BG in collagen sponge that was placed over the site, then figure X sutures to close the area using (4-0 polyglycolic acid/ reverse cutting/ 12 mm) resorbable sutures
Study: NCT01171456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Administration of Metformin or placebo prior to conception to prevent the onset of GDM.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of Metformin or placebo prior to conception to prevent the onset of GDM.
Study: NCT01913080

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Log
Description: The Health Log consists of a permanent booklet and a refillable health log version that is filled out before each doctor's appointment. The permanent booklet has areas to record:~* Personal information and emergency contact(s)~* Physician names and contact information~* Insurance information~* Medications, vitamins and supplements~* Surgeries~* Health history The booklet also includes suggested questions you may want to ask your Rheumatologist about medications, lifestyle, or future/status.~The refillable health log includes questions about pain, fatigue,overall status from the Multi-Dimensional Health Assessment Questionnaire (MDHAQ), and a modified Arthritic Pain and Joint Evaluation. It also has space to write questions for the doctor's visit and prescription refills needed.
Study: NCT02028195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health check
Description: The program includes four components:~Invitation: All participants receive invitation by mail and a prefixed appointment time. A web-based questionnaire including self-reported health (SF12), physical activity, smoking habits and alcohol use/behaviour has to be answered before Health Examination (HE).~The HE include: Blood pressure, waist, weight, lung function test, lipid profile, HbA1c and fitness (Aastrand).~Health profile pamphlet: The participant receives a pamphlet with the results. The persons are stratified into three groups (I) referral to a consultation in general practice (GP) (II) targeted behavioural programs at the health centre (HC) or (III ) no identified need for health promoting follow-up.~Follow-up according to risk-profile: If referred to GP treatment of risk conditions or diseases will follow national guidelines. The GPs were paid 50 Euros per health interview.
Study: NCT01034046

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Carbohydrate Diet
Description: Low carbohydrate diet (45% carbohydrate, 35% fat and 20% protein diet) administered utilizing meal replacements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Carbohydrate Diet
Description: Low carbohydrate diet (45% carbohydrate, 35% fat and 20% protein diet) administered utilizing meal replacements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Fat Diet
Description: Low fat diet (60% carbohydrate, 20% fat and 20% protein diet) administered utilizing meal replacements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Fat Diet
Description: Low fat diet (60% carbohydrate, 20% fat and 20% protein diet) administered utilizing meal replacements.
Study: NCT02655081

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high arginine nutritional supplement (Nestle's Impact AR)
Description: Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy
Study: NCT03031600

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Radiodilution via Daxor BVA-100
Description: The BVA-100 measures the hematocrit and residual plasma radioactivity of each sample in a semi-automated process, and the residual radioactivity is compared from that of the pre-injection sample to determine plasma volume. The plasma volume and BVA-100-measured hematocrit are then used to calculate the red cell volume and actual blood volume. The BVA-100 is FDA approved for blood volume measurement in vivo, has a reported precision of ± 2.5%, and has demonstrated accuracy and specificity in blood volume assessment in clinical and research settings (Van, P.Y., et al., 2011, Borovka, M., et al., 2013).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hemodilution via hematocrit measurement
Description: Hemodilution uses the ideal blood volume and serial hematocrit measures drawn before and after administration of a known quantity of IV fluid to estimate blood volume. Ideal blood volume is calculated using the methods described by Feldschuh and colleagues (Feldschuh, J. and Y. Enson, 1977; Feldschuh, J. and S. Katz, 2007). Hematocrit is measured using the Abbot iSTAT point of care testing device and the lab. Urine output is measured in ml. The ideal blood volume, pre and post-bolus hematocrit, fluid bolus volume, and urine output will be used to calculate estimated blood volume using a mathematical model previously described by the investigators (D'Angelo, M., et al., 2015).
Study: NCT04146142

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperineal prostate biopsy with or without antibiotic prophylaxis
Description: As described above.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transperineal prostate biopsy with or without antibiotic prophylaxis
Description: As described above.
Study: NCT04613726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: group consisted of receiving IV 8 mg ondansetron diluted in 10 ml of normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron
Description: Another comparator group consisted of receivingIV 3 mg granisetron diluted in 10 ml of normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Control group consisted of patients receiving IV 10 ml normal saline
Study: NCT00731172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glatiramer acetate
Description: 20 mg daily subcutaneous injection through week 12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous daiky injection through week 12
Study: NCT00062387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perifosine
Study: NCT05169528

Intervention type: OTHER
Group type: OTHER
Intervention: Colorectal Cancer Prehabilitation Programme
Description: Assessment and Interventions involving the Prehabilitative domains of medical optimisation, exercise prescription, nutrition and mental health optimisation
Study: NCT00891579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed (Alimta)
Description: treatment of single pemetrexed with vitamin supplement until discontinued conditions are met

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib (IRESSA)
Description: treatment of Gefitinib will be applied until discontinued conditions are met